Ellence Research Fund Names 11 Grant Recipients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

PEAPACK, NJ- Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals.

PEAPACK, NJ— Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals. (For more information, contact Lynn Stoltzfus at lynn.stoltzfus@am.pnu.com.)

The 2001 winners are: Glenn Bubley, MD, Beth Israel Deaconess Medical Center, Boston; Joan Bull, MD, University of Texas-Houston Medical School; Luke Dreisbach, MD, Arizona Cancer Center, Tucson; Phil Gold, MD, Swedish Medical Center Tumor Institute, Seattle; Daniel Haller, MD, University of Pennsylvania Cancer Center, Philadelphia; and Jon Herrington, PhD, Scott and White Memorial Hospital, Temple, Texas.

Also, Peter Kennedy, MD, Kenmar Research Institute, Los Angeles; Pam Khosla, MD, Rush-Presbyterian-St. Luke’s Medical Center, Chicago; Silvana Martino, DO, John Wayne Cancer Institute, Santa Monica, California; Lajos Pusztai, PhD, M.D. Anderson; and Christopher Ryan, MD, University of Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content